Primary Condition Treated with Sapropterin
Sapropterin dihydrochloride (Kuvan) primarily benefits patients with tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU), a genetic disorder where the body cannot break down phenylalanine due to deficient phenylalanine hydroxylase activity. Sapropterin acts as a synthetic BH4 cofactor, restoring enzyme function in responsive patients and lowering blood phenylalanine levels.[1][2]
How Sapropterin Works in PKU
In PKU, high phenylalanine buildup damages the brain if untreated. Sapropterin enables residual enzyme activity in about 20-50% of patients, allowing a less strict diet. Patients undergo a BH4 loading test to confirm responsiveness—typically a 30% phenylalanine reduction within 24 hours.[1][3]
Who Qualifies for Sapropterin Therapy
Primarily children and adults with mild to moderate hyperphenylalaninemia (PKU variants). It's FDA-approved for ages 1 month and older who respond positively. Non-responsive patients rely on dietary phenylalanine restriction and medical foods.[2]
Effectiveness and Clinical Evidence
Trials showed responsive PKU patients on sapropterin (10-20 mg/kg/day) reduced phenylalanine by 30-50% versus placebo, with sustained benefits over 6-10 years in long-term studies. About 20% achieve normal levels without diet changes.[3][4]
Alternatives if Not Responsive
Non-responders use pegvaliase (Palynziq), an enzyme substitute injection, or traditional low-phenylalanine diets. Gene therapy trials are emerging but not approved.[1]
Common Side Effects and Monitoring
Headache, runny nose, and sore throat affect 10-20% of users. Rare risks include hypersensitivity. Blood phenylalanine monitoring is required monthly.[2]
Sources:
[1] FDA Label for Kuvan
[2] DrugPatentWatch.com - Sapropterin
[3] NEJM Study on Sapropterin in PKU
[4] Long-term PKU Trial Data